Radiographic Analysis Using PureGen Versus Autologous Bone in Posterolateral Fusion (PLF)

NCT ID: NCT01294007

Last Updated: 2022-11-02

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 1 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-02-28
• Study Completion Date: 2013-11-30

Brief Summary

The purpose of this study is to evaluate the rate and quality of fusion of PureGen Osteoprogenitor Cell Allograft, compared to autograft bone in instrumented posterolateral fusion (PLF) procedures.

Detailed Description

This is a prospective, multi-center, observational, self-control study assessing screened and consented subjects undergoing instrumented posterolateral fusion for degenerative disc disease (DDD) at 1 to 2 contiguous levels between L1 and S1.

Patients diagnosed with DDD will be screened for enrollment based on inclusion and exclusion criteria outlined in this protocol. Subjects who are successfully screened and sign an informed consent will undergo PLF surgery utilizing PureGen, Alphagraft ProFuse Demineralized Bone Scaffold (DBS), and ZODIAC, Illico, or Xenon Fixation system (pedicle screw and rod fixation system)

Subjects will be followed at 6 weeks, 3, 6, 12 and 24 month post-operative visits. Standard radiographs will be taken at these visits to evaluate fusion rate and quality. Oswestry Disability Index (ODI) and Visual Analog Scale (VAS) self-assessment questionnaires and neurological exams will be administered to measure pain and function scores. A computerized tomography (CT) scan will be taken at the 6-month to further assess rate and quality of fusion. A conditional 12 and 24 month post operative CT may also be taken. Procedure related and PureGen related adverse events will be monitored throughout the study.

Conditions

Lumbar Degenerative Disc Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Study Graft Composite

AlphaGraft ProFuse Demineralized Bone Scaffold are soaked in PureGen according to Preparation for Use and handling technique. The graft composite is placed on the randomized study side contralateral to the autograft bone graft per surgeon's standard technique for PLF. The wound is closed according to surgeon's standard technique.

Post operative care will be according to the site specific standard of care. An avoidance of heavy physical activity and limitations on working, lifting, bending etc. are common precautions post procedure. The decision to use a post operative orthosis is left to the discretion of the Investigator.

Group Type: EXPERIMENTAL

PureGen Osteoprogenitor Cell Allograft

Intervention Type: BIOLOGICAL

PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.

Control Graft Composite

Contralateral to the study graft composite, placement of posterolateral fusion graft composite containing iliac crest bone (5 cc/level/side) and local autograft composite (equal volume split with study side). Supplemental posterior pedicle screw fixation utilizing Zodiac, Illico or Xenon Spinal Fixation system.

• A defined volume of iliac crest bone graft (indicated in table 2) is harvested and combined with 50% of the previously harvest morselized local bone
• The graft composite is placed on the randomized control side using standard technique for PLF

Group Type: ACTIVE_COMPARATOR

Autograft bone

Intervention Type: PROCEDURE

Iliac Crest and Local Autograft Bone

Interventions

PureGen Osteoprogenitor Cell Allograft

PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.

Intervention Type: BIOLOGICAL

Autograft bone

Iliac Crest and Local Autograft Bone

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Symptomatic lumbar degenerative disc disease in up to two contiguous levels between L1 and S1
• Subjects with back and/or leg pain indicated for posterior stabilization with or without decompression at any level and posterolateral fusion (PLF)
• Unresponsive to conservative treatment for at least 6 months
• Radiographic evidence of primary diagnosis

Exclusion Criteria

• More than 2 levels requiring posterolateral fusion
• Spondylolisthesis greater than Grade I
• Prior failed fusion surgery at any lumbar level(s)
• Systemic or local infection in the disc or cervical spine, past or present
• Active systemic disease
• Osteoporosis, osteomalacia, or other metabolic bone disease that would significantly inhibit bone healing
• Use of other bone graft, Bone Morphogenetic Protein (BMP) or bone graft substitutes in addition to or in place of those products specified
• BMI greater than 40
• Use of post operative Spinal Cord Stimulator (SCS)
• Known or suspected history of alcohol and/or drug abuse
• Involved in pending litigation or worker's compensation related to the spine
• Pregnant or planning to become pregnant during the course of the study
• Insulin-dependent diabetes mellitus
• Life expectancy less than duration of study
• Any significant psychological disturbance that could impair consent process or ability to complete self-assessment questionnaires
• Undergoing chemotherapy or radiation treatment, or chronic use of oral or injected steroids or prolonged use of non-steroidal anti-inflammatory drugs.
• Known history of hypersensitivity or anaphylactic reaction to dimethyl sulfoxide (DMSO)

• Minimum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Alphatec Spine, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Beverly Hills, California, United States

Countries

United States

Other Identifiers

PRO-000061

Identifier Type: -

Identifier Source: org_study_id